The role of arginine vasopressin in the development of tolerance to ethanol in normal and Brattleboro rats

Dennis L. Hjeresen, Deborah J. Brief, Diane L. Amend, Daniel Dorsa, Stephen C. Woods

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Administration of AVP and related peptide fragments following ethanol (EtOH) administration has been shown to enhance retention of tolerance to ethanol. The present studies were designed specifically to: (1) examine the influence of AVP given concurrently with EtOH on the development of tolerance to the ataxic and hypothermic effects of EtOH in Long-Evans rats, and (2) to determine if tolerance to these effects develops in Brattleboro rats which are deficient in AVP. In Experiment 1, EtOH (2.5 g/kg, 15% v/v) was administered IP to 2 groups of rats in combination with a SC injection of either AVP (6 μg/kg) or an equal volume of saline. Two additional control groups received IP saline injections in combination with either saline or AVP. After 13 days, EtOH-treated rats were significantly more tolerant than saline-treated animals. AVP significantly increased the hypothermic and ataxic effects of EtOH and failed to enhance tolerance development. AVP delayed the extinction of tolerance to the hypothermic (but not the ataxic) effects of ethanol when administered during the extinction phase to rats previously treated with EtOH. In Experiment 2, Brattleboro rats were injected with EtOH or an equivalent volume of saline and tested for ataxia and hypothermia. Rats receiving EtOH failed to demonstrate significant tolerance to either effect of ethanol after 12 treatment days.

Original languageEnglish (US)
Pages (from-to)193-200
Number of pages8
JournalPeptides
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Brattleboro Rats
Arginine Vasopressin
Rats
Ethanol
Long Evans Rats
Injections
Peptide Fragments
Ataxia
Hypothermia
Control Groups
Animals
Experiments

Keywords

  • Arginine vasopressin
  • Brattleboro rats
  • Ethanol
  • Tolerance
  • Vasopressins

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

The role of arginine vasopressin in the development of tolerance to ethanol in normal and Brattleboro rats. / Hjeresen, Dennis L.; Brief, Deborah J.; Amend, Diane L.; Dorsa, Daniel; Woods, Stephen C.

In: Peptides, Vol. 9, No. SUPPL. 1, 1988, p. 193-200.

Research output: Contribution to journalArticle

Hjeresen, Dennis L. ; Brief, Deborah J. ; Amend, Diane L. ; Dorsa, Daniel ; Woods, Stephen C. / The role of arginine vasopressin in the development of tolerance to ethanol in normal and Brattleboro rats. In: Peptides. 1988 ; Vol. 9, No. SUPPL. 1. pp. 193-200.
@article{f44f7bad79854c8db888f8b27351eea6,
title = "The role of arginine vasopressin in the development of tolerance to ethanol in normal and Brattleboro rats",
abstract = "Administration of AVP and related peptide fragments following ethanol (EtOH) administration has been shown to enhance retention of tolerance to ethanol. The present studies were designed specifically to: (1) examine the influence of AVP given concurrently with EtOH on the development of tolerance to the ataxic and hypothermic effects of EtOH in Long-Evans rats, and (2) to determine if tolerance to these effects develops in Brattleboro rats which are deficient in AVP. In Experiment 1, EtOH (2.5 g/kg, 15{\%} v/v) was administered IP to 2 groups of rats in combination with a SC injection of either AVP (6 μg/kg) or an equal volume of saline. Two additional control groups received IP saline injections in combination with either saline or AVP. After 13 days, EtOH-treated rats were significantly more tolerant than saline-treated animals. AVP significantly increased the hypothermic and ataxic effects of EtOH and failed to enhance tolerance development. AVP delayed the extinction of tolerance to the hypothermic (but not the ataxic) effects of ethanol when administered during the extinction phase to rats previously treated with EtOH. In Experiment 2, Brattleboro rats were injected with EtOH or an equivalent volume of saline and tested for ataxia and hypothermia. Rats receiving EtOH failed to demonstrate significant tolerance to either effect of ethanol after 12 treatment days.",
keywords = "Arginine vasopressin, Brattleboro rats, Ethanol, Tolerance, Vasopressins",
author = "Hjeresen, {Dennis L.} and Brief, {Deborah J.} and Amend, {Diane L.} and Daniel Dorsa and Woods, {Stephen C.}",
year = "1988",
doi = "10.1016/0196-9781(88)90244-6",
language = "English (US)",
volume = "9",
pages = "193--200",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The role of arginine vasopressin in the development of tolerance to ethanol in normal and Brattleboro rats

AU - Hjeresen, Dennis L.

AU - Brief, Deborah J.

AU - Amend, Diane L.

AU - Dorsa, Daniel

AU - Woods, Stephen C.

PY - 1988

Y1 - 1988

N2 - Administration of AVP and related peptide fragments following ethanol (EtOH) administration has been shown to enhance retention of tolerance to ethanol. The present studies were designed specifically to: (1) examine the influence of AVP given concurrently with EtOH on the development of tolerance to the ataxic and hypothermic effects of EtOH in Long-Evans rats, and (2) to determine if tolerance to these effects develops in Brattleboro rats which are deficient in AVP. In Experiment 1, EtOH (2.5 g/kg, 15% v/v) was administered IP to 2 groups of rats in combination with a SC injection of either AVP (6 μg/kg) or an equal volume of saline. Two additional control groups received IP saline injections in combination with either saline or AVP. After 13 days, EtOH-treated rats were significantly more tolerant than saline-treated animals. AVP significantly increased the hypothermic and ataxic effects of EtOH and failed to enhance tolerance development. AVP delayed the extinction of tolerance to the hypothermic (but not the ataxic) effects of ethanol when administered during the extinction phase to rats previously treated with EtOH. In Experiment 2, Brattleboro rats were injected with EtOH or an equivalent volume of saline and tested for ataxia and hypothermia. Rats receiving EtOH failed to demonstrate significant tolerance to either effect of ethanol after 12 treatment days.

AB - Administration of AVP and related peptide fragments following ethanol (EtOH) administration has been shown to enhance retention of tolerance to ethanol. The present studies were designed specifically to: (1) examine the influence of AVP given concurrently with EtOH on the development of tolerance to the ataxic and hypothermic effects of EtOH in Long-Evans rats, and (2) to determine if tolerance to these effects develops in Brattleboro rats which are deficient in AVP. In Experiment 1, EtOH (2.5 g/kg, 15% v/v) was administered IP to 2 groups of rats in combination with a SC injection of either AVP (6 μg/kg) or an equal volume of saline. Two additional control groups received IP saline injections in combination with either saline or AVP. After 13 days, EtOH-treated rats were significantly more tolerant than saline-treated animals. AVP significantly increased the hypothermic and ataxic effects of EtOH and failed to enhance tolerance development. AVP delayed the extinction of tolerance to the hypothermic (but not the ataxic) effects of ethanol when administered during the extinction phase to rats previously treated with EtOH. In Experiment 2, Brattleboro rats were injected with EtOH or an equivalent volume of saline and tested for ataxia and hypothermia. Rats receiving EtOH failed to demonstrate significant tolerance to either effect of ethanol after 12 treatment days.

KW - Arginine vasopressin

KW - Brattleboro rats

KW - Ethanol

KW - Tolerance

KW - Vasopressins

UR - http://www.scopus.com/inward/record.url?scp=17044450313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044450313&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(88)90244-6

DO - 10.1016/0196-9781(88)90244-6

M3 - Article

C2 - 2856644

AN - SCOPUS:17044450313

VL - 9

SP - 193

EP - 200

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - SUPPL. 1

ER -